Nanopore Sequencing in Ophthalmology

Nanopore Sequencing in Ophthalmology - a Paradigm Shift in Pathogen Determination?

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05372861

Enrollment

Registered

2022-05-13

Start date

2022-04-22

Completion date

2027-12-01

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endophthalmitis

Keywords

Endophthalmitis, Nanopore sequencing, Next Generation Sequencing

Brief summary

In this pilot study, the feasibility of the Oxford Nanopore MinION to identify pathogens from vitrectomy samples in eyes with endophthalmitis shall be assessed. The MinION is a low cost commercially available device for DNA/ RNA analysis that, in studies, has been used for pathogen determination in various infectious diseases as well as for the genetic characterization of hematologic tumors.

Detailed description

Vitreous samples and anterior chamber taps from eyes with endophthalmitis are taken during routine vitrectomy. The gathered samples are divided in half to undergo routine culture for microbial growth and nanopore sequencing with the MinION Mk1b, a commercially available device for DNA/RNA sequencing. Base reads from Nanopore sequencing are then compared with available libraries for pathogen identification. The Nanopore sequencing results for pathogens are compared versus the results of the microbiological culture of the same eye as the gold standard. Clinical features and visual function before and after vitrectomy are gathered from patient charts. Treatment is not altered due to results of the Nanopore sequencing.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Inclusion criteria

* Eyes of patients with endophthalmitis

Exclusion criteria

* No informed consent possible * Participation in other studies

Design outcomes

Primary

Measure	Time frame	Description
Pathogen detection	In vitro analysis after vitrectomy for endophthalmitis. Start of analysis: Within the next working day after sample acquisition. Time for Nanopore sequencing: Approximately up to 10 hours. Time for culture: 24 hours up to 14 days.	Pathogens detected by Nanopore sequencing versus microbiologic culture

Secondary

Measure	Time frame	Description
Time to pathogen detection	Time measured from start of analysis until arrival of results. Time for Nanopore sequencing: Approximately up to 10 hours. Time for culture: 24 hours up to 14 days.	Time in days from gathering of the sample until arrival of results
Visual acuity	Gathered from patient charts two months after vitrectomy.	Visual acuity measured with Snellen charts

Countries

Austria

Contacts

Primary ContactMichael Sommer, MD

michael.sommer@medunigraz.at004331638531033

Backup ContactGerald Seidel, MD, PhD

gerald.seidel@medunigraz.at004331638580714

Outcome results